Merve Oyken

Merve Oyken

Auto-generated profile, based on publicly available information

Merve Oyken

Department of Cell and Chemical Biology, Division of Chemical Biology and Drug Discovery, Leiden University Medical Center, Einthovenweg 20, Leiden 2333 ZC, The Netherlands

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2015 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
HAHesna Begum Akman
Hesna Begum Akman
MOMerve Oyken
Merve Oyken
TTTaner Tuncer
Taner Tuncer
TCTolga Can
Tolga Can
AEAYSE ERSON-BENSAN
AYSE ERSON-BENSAN
Alternative polyadenylation (APA) plays a role in gene expression regulation generally by shortening of 3′UTRs (untranslated regions) upon proliferative signals and relieving microRNA-mediated repression. Owing to high proliferative indices of triple negative breast cancers (TNBCs), we hypothesized APA to cause 3′UTR length changes in this aggressive subgroup of breast cancers. Our probe-based meta-analysis approach identified 3′UTR length alterations where the significant majority was shortening events (∼70%, 113 of 165) of mostly proliferation-related transcripts in 520 TNBC patients compared with controls. Representative shortening events were further investigated for their microRNA binding potentials by computational predictions and dual-luciferase assay. In silico-predicted 3′UTR shortening events were experimentally confirmed in patient and cell line samples. To begin addressing the underlying mechanisms, we found CSTF2 (cleavage stimulation factor 2), a major regulator of 3′UTR shortening to be up-regulated in response to epidermal growth factor (EGF). EGF treatment also resulted with further shortening of the 3′UTRs. To investigate the contribution of CSTF2 and 3′UTR length alterations to the proliferative phenotype, we showed pharmacological inhibition of the EGF pathway to lead to a reduction in CSTF2 levels. Accordingly, RNAi-induced silencing of CSTF2 decreased the proliferative rate of cancer cells. Therefore, our computational and experimental approach revealed a pattern of 3′UTR length changes in TNBC patients and a potential link between APA and EGF signaling. Overall, detection of 3′UTR length alterations of various genes may help the discovery of new cancer-related genes, which may have been overlooked in conventional microarray gene expression analyses.

30 October 2021 in Oncogene
Verified
Journal Article
Closed access
PDF file
ECEsra Cicek
Esra Cicek
AÇAyça Çırçır
Ayça Çırçır
MOMerve Oyken
Merve Oyken
ÖÇÖzge Akbulut Çalışkan
Özge Akbulut Çalışkan
DDDidem Naz Dioken
Didem Naz Dioken
AEAYSE ERSON-BENSAN
AYSE ERSON-BENSAN

1 July 2017 in Neoplasia
Verified
Journal Article
Open access
OBOguzhan Begik
Oguzhan Begik
MOMerve Oyken
Merve Oyken
TATuna Cinkilli Alican
Tuna Cinkilli Alican
TCTolga Can
Tolga Can
AEAYSE ERSON-BENSAN
AYSE ERSON-BENSAN
Certain aspects of diagnosis, prognosis, and treatment of cancer patients are still important challenges to be addressed. Therefore, we propose a pipeline to uncover patterns of alternative polyadenylation (APA), a hidden complexity in cancer transcriptomes, to further accelerate efforts to discover novel cancer genes and pathways. Here, we analyzed expression data for 1045 cancer patients and found a significant shift in usage of poly(A) signals in common tumor types (breast, colon, lung, prostate, gastric, and ovarian) compared to normal tissues. Using machine-learning techniques, we further defined specific subsets of APA events to efficiently classify cancer types. Furthermore, APA patterns were associated with altered protein levels in patients, revealed by antibody-based profiling data, suggesting functional significance. Overall, our study offers a computational approach for use of APA in novel gene discovery and classification in common tumor types, with important implications in basic research, biomarker discovery, and precision medicine approaches.

14 August 2014 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
AEAyse Selcen Oguz Erdogan
Ayse Selcen Oguz Erdogan
NONihan Ozdemirler
Nihan Ozdemirler
MOMerve Oyken
Merve Oyken
MAMurat Alper
Murat Alper
AEAYSE ERSON-BENSAN
AYSE ERSON-BENSAN

7 May 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
YJYuqing Jia
Yuqing Jia
MOMerve Oyken
Merve Oyken
RKRobbert Q. Kim
Robbert Q. Kim
RTRayman T.N. Tjokrodirijo
Rayman T.N. Tjokrodirijo
ARArnoud H. de Ru
Arnoud H. de Ru
ASAysegul Sapmaz
Aysegul Sapmaz
The integration of diverse chemical tools like small-molecule inhibitors, activity-based probes (ABPs), and proteolysis targeting chimeras (PROTACs) advances clinical drug discovery and facilitates the exploration of various biological facets of targeted proteins. Here, we report the development of such a chemical toolbox for the human Parkinson disease protein 7 (PARK7/DJ-1) implicated in Parkinson's disease and cancers. By combining structure-guided design, miniaturized library synthesis, and high-throughput screening, we identified two potent compounds, JYQ-164 and JYQ-173, inhibiting PARK7 in vitro and in cells by covalently and selectively targeting its critical residue, Cys106. Leveraging JYQ-173, we further developed a cell-permeable Bodipy probe, JYQ-196, for covalent labeling of PARK7 in living cells and a first-in-class PARK7 degrader JYQ-194 that selectively induces its proteasomal degradation in human cells. Our study provides a valuable toolbox to enhance the understanding of PARK7 biology in cellular contexts and opens new opportunities for therapeutic interventions.